Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular cells,...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concomitant use of risankizumab in moderate-to-severe psoriasis induced by ofatumumab in a patient with relapsing-remitting multiple sclerosis.

Medicina clinica·2026
Same author

Anifrolumab for refractory lupus panniculitis: Sustained remission in a long-standing case.

Medicina clinica·2026
Same author

ACOX1 Gain-of-Function and De Novo ROBO1 Variant in ACOX1-sEDD.

Pediatric dermatology·2026
Same author

Efficacy and Safety of Guselkumab in Real-World Evidence: A Systematic Review and Meta-Analysis.

Journal of clinical medicine·2026
Same author

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS).

Pharmacy (Basel, Switzerland)·2026
Same author

N-acetylcysteine: reinventing classic pharmacology through skin.

European journal of dermatology : EJD·2026
Same journal

Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.

American journal of clinical dermatology·2026
Same journal

A Systematic Review of the Clinical Impact of GLP-1 Receptor Agonists in Hidradenitis Suppurativa.

American journal of clinical dermatology·2026
Same journal

What's New in Photoprotection?

American journal of clinical dermatology·2026
Same journal

Primary Cutaneous Cryptococcosis in Immunocompetent Patients: Recognition and Management.

American journal of clinical dermatology·2026
Same journal

Practical Therapeutic Strategies for Acne-Induced Hyperpigmentation Across all Skin Types.

American journal of clinical dermatology·2026
Same journal

Dermatologic Adverse Events Associated with T-Cell Engager Therapy.

American journal of clinical dermatology·2026
See all related articles
  1. Home
  3. Rethinking Head And Neck Atopic Dermatitis: Pathogenic Axes And Emerging Therapeutic Directions.
  1. Home
  3. Rethinking Head And Neck Atopic Dermatitis: Pathogenic Axes And Emerging Therapeutic Directions.

Related Experiment Videos

Rethinking Head and Neck Atopic Dermatitis: Pathogenic Axes and Emerging Therapeutic Directions.

Francisco José Navarro-Triviño1,2,3, Ricardo Ruiz-Villaverde4,5, Tiago Torres6,7,8

  • 1Servicio de Dermatología, Hospital Universitario San Cecilio, Avda. de la Investigación, s/n, 18006, Granada, Spain. fntmed@gmail.com.

American Journal of Clinical Dermatology
|June 22, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Head and neck atopic dermatitis is a distinct condition influenced by skin barrier, microbiome, and immune factors. New therapies targeting specific pathways offer improved management for this challenging phenotype.

Related Experiment Videos

Area of Science:

  • Dermatology
  • Immunology
  • Genetics

Background:

  • Head and neck atopic dermatitis (HNAD) is a distinct phenotype.
  • It involves regional barrier defects, unique microenvironment, and specific immune pathways.

Purpose of the Study:

  • To review pathogenic hallmarks of HNAD.
  • To integrate mechanistic and clinical data.
  • To discuss evolving therapeutic strategies for HNAD.

Main Methods:

  • Literature review of pathogenic hallmarks.
  • Integration of mechanistic and clinical data.
  • Discussion of evolving therapeutic strategies.

Main Results:

  • HNAD is shaped by barrier fragility, sebaceous microenvironment, and microbiome.
  • Immune signature involves type 2, 17, and 22 pathways.
  • Paradoxical inflammation seen with IL-4Rα blockade (e.g., Dupilumab).

    • Conclusions:

    • HNAD requires phenotype-driven, region-specific management.
    • IL-13-selective biologics, JAK inhibitors, and T-cell pathway agents show promise.
    • Further research needed for comparative data and optimal treatment selection.